Oncolytics Biotech Presents Results of Pelareorep + Bortezomib in P-Ib Study for the Treatment of Multiple Myeloma at the AACR 2022
Shots:
- The P-Ib POC study evaluates pelareorep + bortezomib (proteasome inhibitor) in patients with r/r MM
- The results showed that the combination was well-tolerated and led to a prolonged PFS of ~3yrs. in patients with r/r MM while biomarker data showed increased infiltration of T & NK cells correlated with clinical response & changes in T cell clonality
- Pelareorep is currently being evaluated in an ongoing P-I (NCI-9603) trial in combination with Kyprolis (carfilzomib) & the trial is being conducted in collaboration with the US NCI while the (WINSHIP 4398-18) trial evaluate pelareorep + carfilzomib and nivolumab for the same indication
Ref: PR Newswire | Image: Oncolytics
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
